Displaying all 8 publications

Abstract:
Sort:
  1. Locarnini S
    Med J Malaysia, 2005 Jul;60 Suppl B:116-24.
    PMID: 16108191
    Matched MeSH terms: Viral Hepatitis Vaccines*
  2. Ton SH, Noriah R, Duraisamy G
    Indian J Med Res, 1988 Jun;87:542-4.
    PMID: 3240935
    Matched MeSH terms: Viral Hepatitis Vaccines/immunology*
  3. Isahak I, Abdul Malik Y, Hakim AS, Baharin R
    Singapore Med J, 1990 Aug;31(4):314-6.
    PMID: 2147781
    Fifty medical students were screened for hepatitis B serological markers of whom 42 students entered the study. Those who were found to be negative for all markers were vaccinated with 1.0 ml (20 mcg HBsAg) Engerix-B vaccine intramuscularly in the deltoid region according to the 0, 1, 6 month schedule. Blood samples were taken at 1, 2, 3, 6, 9 months. One month following the first dose, 7% showed detectable AntiHBs with a GMT of 11 IU/I. By the sixth month, just before the third dose was given, 79% seroconverted with a GMT of 2952 IU/I. Three months following the third dose all had seroconverted with a GMT of 18,381 IU/I. No serious adverse reactions were noted and none of the subjects showed evidence of hepatitis B infection during the study. This study thus confirms the high immunogenicity and safety of recombinant yeast-extract hepatitis B vaccine.
    Matched MeSH terms: Viral Hepatitis Vaccines/administration & dosage*; Viral Hepatitis Vaccines/adverse effects; Viral Hepatitis Vaccines/immunology
  4. Yaacob HB, Samaranayake LP
    J Oral Pathol Med, 1989 Apr;18(4):236-9.
    PMID: 2769596
    A postal survey of 730 Malaysian dental practitioners was undertaken to assess their awareness and acceptance of the plasma derived hepatitis B vaccine. Only 32% of the 325 practitioners who responded had been vaccinated, 41% intended to be and 15% categorically refused vaccination. The main reservations about vaccine acceptance were fear of side effects including AIDS, cost of the vaccine and lack of information. Vaccine efficacy was not confirmed by serology in two-thirds of the vaccinees and two-fifths of the respondents were unaware that 5% of the vaccinees do not develop a successful antibody response after vaccination. Seventy-eight percent of dentists believed that their risk of contracting hepatitis B was high or very high while 71% recalled having received needle stick injuries in the 3 yr prior to the survey. Only 13% of respondents were aware of delta hepatitis while 63% were aware of non-A non-B hepatitis. The survey has highlighted the need for dissemination of information on hepatitis B vaccine among dentists in Malayasia.
    Matched MeSH terms: Viral Hepatitis Vaccines*
  5. Othman SN, Zainol Rashid Z, Abdul Wahab A, Abdul Samat MN, Ding CH, Ali UK
    Malays J Pathol, 2018 Dec;40(3):295-302.
    PMID: 30580360
    INTRODUCTION: Infant hepatitis B vaccination was introduced into the Expanded Programme on Immunisation (EPI) in Malaysia in 1989. This study aimed to investigate seroprevalence of hepatitis B among UKM pre-clinical medical students, born between 1991 and 1995, and had their infant vaccination more than 20 years ago.

    MATERIALS AND METHODS: A prospective, cross-sectional study involving 352 students, comprising 109 (31.0%) males and 243 (69.0%) females. Blood specimens were tested for anti-HBs, where levels of ≥10 mIU/mL was considered reactive and protective. Students with non-reactive levels were given a 20 μg HBV vaccine booster. Anti-HBs levels were tested six weeks after the first booster dose. Those with anti-HBs <10 mIU/mL were then given another two booster doses, at least one month apart. Anti-HBs levels were tested six weeks after the third dose.

    RESULTS: Ninety-seven students (27.6%) had anti-HBs ranging from 10 to >1000 mIU/mL while 255 (72.4%) had anti-HBs <10 mIU/mL. After one booster dose, 208 (59.1%) mounted anti-HBs ≥10 mIU/mL. Among the remaining 47 (13.3%), all except two students (0.6%) responded following completion of three vaccination doses. They were negative for HBsAg and anti-HBcore antibody, thus regarded as non-responders.

    CONCLUSIONS: Anti-HBs levels waned after 20 years post-vaccination, where more than 70% were within non-reactive levels. For healthcare workers, a booster dose followed by documenting anti-HBs levels of ≥10 mIU/mL may be recommended, to guide the management of post-exposure prophylaxis. Pre-booster anti-HBs testing may not be indicated. Serological surveillance is important in long-term assessment of HBV vaccination programs. No HBV carrier was detected.

    Matched MeSH terms: Viral Hepatitis Vaccines*
  6. Wilkinson IE
    Med J Aust, 1992 May 18;156(10):741.
    PMID: 1535682
    Matched MeSH terms: Viral Hepatitis Vaccines*
  7. Razak IA, Latifah RJ, Nasruddin J, Esa R
    Clin Prev Dent, 1991 Jul-Aug;13(4):22-4.
    PMID: 1884572
    A questionnaire was mailed to 1217 dentists whose names appear in the Dentist Register of 1987 in order to assess their awareness and acceptance of hepatitis B vaccine and their pattern of glove usage. Almost all the respondents (99.6%) were aware of the availability of the hepatitis B vaccine yet only 44.8% have received the vaccine. This is in spite of the fact that the majority (61.2%) of the vaccine non-acceptors have no reservations concerning the vaccine. About 71% and 63% of the vaccine-acceptors and non-acceptors respectively believed that the risk of their contracting hepatitis B was high or very high. About 22% of the vaccine non-acceptors never used gloves when treating patients as compared to 9% among vaccine acceptors. Overall, about 78% of the respondents have experienced needleprick injuries in the 3 years preceding the survey.
    Matched MeSH terms: Viral Hepatitis Vaccines
  8. Mah GK, Yeo A
    Ann Acad Med Singap, 1990 May;19(3):339-43.
    PMID: 2144101
    Blood samples from 1,600 persons who sought immunisation against hepatitis B in private clinics in Singapore in 1988-1989 were screened for two viral markers. Of that total, 4.81% were positive for HBsAg and 17.31% had anti-HBs levels greater than 10 mIU/ml, indicating that about 22.12% of the general population would not benefit from immunisation. Preimmunisation screening will identify persons not requiring the hepatitis B vaccine and thus, avoid wastage. When immunisation has already been performed without screening, recall for post-immunisation screening should be considered in order to detect the infectious hepatitis B carriers. Data in this study indicates that at this point in time, it is important to immunise adolescents and adults, in addition to neonates and children.
    Matched MeSH terms: Viral Hepatitis Vaccines
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links